Lawrence G Kogan1, S Lindsey Davis2, Gabriel A Brooks1,3. 1. Department of Medicine, Rhode Island Hospital, Providence, RI, USA. 2. University of Colorado Cancer Center, Aurora, CO, USA. 3. Norris Cotton Cancer Center, Lebanon, NH, USA.
Abstract
BACKGROUND: FOLFOX (folinic acid, 5-fluorouracil and oxaliplatin) is the most commonly used chemotherapy regimen for the treatment of colorectal cancer. FOLFOX is administered in 14-day cycles, though toxicities frequently lead to unplanned delays. We report the incidence of unplanned delays among patients receiving FOLFOX and describe the reasons for delays. METHODS: We conducted a retrospective analysis of patients receiving FOLFOX chemotherapy for colorectal cancer. Patients were treated at one of two tertiary cancer centers between January 2012 and April 2016. Cycles 2-6 were assessed for delays, and treatments were considered delayed when the interval from prior treatment was >18 days. Reasons for unplanned delays were categorized based on review of clinical records. RESULTS: We identified 214 patients receiving FOLFOX as standard-of-care therapy. The median age was 59 years, and 55% were female. Of 961 evaluable treatment cycles, 124 (13%) had unplanned delays, and 92 of 214 patients (43%) had one or more unplanned delays in cycles 2-6. Cytopenias (neutropenia and/or thrombocytopenia) were the most common cause of unplanned delays, affecting 34% of patients and accounting for 74 of 124 unplanned delays (60%). CONCLUSIONS: Delays are common during FOLFOX chemotherapy, with 43% of patients having at least one unplanned delay prior to completing cycle 6. Neutropenia and thrombocytopenia were the leading causes of unplanned delays. Our findings justify the development of systematic approaches for preventing unplanned delays, such as standardized laboratory treatment criteria and/or proactive dose adjustment strategies. 2019 Journal of Gastrointestinal Oncology. All rights reserved.
BACKGROUND: FOLFOX (folinic acid, 5-fluorouracil and oxaliplatin) is the most commonly used chemotherapy regimen for the treatment of colorectal cancer. FOLFOX is administered in 14-day cycles, though toxicities frequently lead to unplanned delays. We report the incidence of unplanned delays among patients receiving FOLFOX and describe the reasons for delays. METHODS: We conducted a retrospective analysis of patients receiving FOLFOX chemotherapy for colorectal cancer. Patients were treated at one of two tertiary cancer centers between January 2012 and April 2016. Cycles 2-6 were assessed for delays, and treatments were considered delayed when the interval from prior treatment was >18 days. Reasons for unplanned delays were categorized based on review of clinical records. RESULTS: We identified 214 patients receiving FOLFOX as standard-of-care therapy. The median age was 59 years, and 55% were female. Of 961 evaluable treatment cycles, 124 (13%) had unplanned delays, and 92 of 214 patients (43%) had one or more unplanned delays in cycles 2-6. Cytopenias (neutropenia and/or thrombocytopenia) were the most common cause of unplanned delays, affecting 34% of patients and accounting for 74 of 124 unplanned delays (60%). CONCLUSIONS: Delays are common during FOLFOX chemotherapy, with 43% of patients having at least one unplanned delay prior to completing cycle 6. Neutropenia and thrombocytopenia were the leading causes of unplanned delays. Our findings justify the development of systematic approaches for preventing unplanned delays, such as standardized laboratory treatment criteria and/or proactive dose adjustment strategies. 2019 Journal of Gastrointestinal Oncology. All rights reserved.
Authors: Carin A T C Lunenburg; Linda M Henricks; Henk-Jan Guchelaar; Jesse J Swen; Maarten J Deenen; Jan H M Schellens; Hans Gelderblom Journal: Eur J Cancer Date: 2015-12-21 Impact factor: 9.162
Authors: J Randolph Hecht; Madhavan Pillai; Russell Gollard; William Heim; Forrest Swan; Ravi Patel; Lyndah Dreiling; May Mo; Imtiaz Malik Journal: Clin Colorectal Cancer Date: 2010-04 Impact factor: 4.481
Authors: Maarten J Deenen; Didier Meulendijks; Annemieke Cats; Marjolein K Sechterberger; Johan L Severens; Henk Boot; Paul H Smits; Hilde Rosing; Caroline M P W Mandigers; Marcel Soesan; Jos H Beijnen; Jan H M Schellens Journal: J Clin Oncol Date: 2015-11-16 Impact factor: 44.544
Authors: S Yousuf Zafar; Jeffrey M Peppercorn; Deborah Schrag; Donald H Taylor; Amy M Goetzinger; Xiaoyin Zhong; Amy P Abernethy Journal: Oncologist Date: 2013-02-26
Authors: Carmen J Allegra; Greg Yothers; Michael J O'Connell; Saima Sharif; Linda H Colangelo; Samia H Lopa; Nicholas J Petrelli; Richard M Goldberg; James N Atkins; Thomas E Seay; Louis Fehrenbacher; Seamus O'Reilly; Luis Chu; Catherine A Azar; Norman Wolmark Journal: J Clin Oncol Date: 2009-05-04 Impact factor: 44.544
Authors: Jung Han Kim; Moo Jun Baek; Byung-Kwon Ahn; Dae Dong Kim; Ik Yong Kim; Jin Soo Kim; Byung-Noe Bae; Bong-Gun Seo; Sang Hun Jung; Kwan Hee Hong; Hungdai Kim; Dong Guk Park; Ji Hye Lee Journal: J Cancer Date: 2016-01-01 Impact factor: 4.207
Authors: Renata Ferrarotto; Ian Anderson; Balazs Medgyasszay; Maria Rosario García-Campelo; William Edenfield; Trevor M Feinstein; Jennifer M Johnson; Sujith Kalmadi; Philip E Lammers; Alfredo Sanchez-Hernandez; Yili Pritchett; Shannon R Morris; Rajesh K Malik; Tibor Csőszi Journal: Cancer Med Date: 2021-08-18 Impact factor: 4.452